Anti-Obesity Cell Therapy Development

Overview

Obesity is a prevalent condition and is often associated with adipose tissue dysfunction. Increased understanding of obesity and its metabolic complications has given rise to novel anti-obesity therapeutic approaches targeting adipose tissue, including cell and Gene Therapy. Protheragen offers a tailor-made one-stop service for anti-obesity cell therapy development based on our extensive expertise and well-established cell therapy development platform. Our dedicated team of professionals is well-versed in the complexities of obesity and facilitates all stages of anti-obesity cell therapy development and pre-clinical studies through innovative and rigorous research.

Driving the Development of Innovative Anti-Obesity Therapies Through Tailored Solutions

We are at the forefront of cell therapy development and are committed to advancing this novel technology. Our team gathers many research scientists with deep academic backgrounds and practical experience in obesity, allowing us to meet our clients' research needs more precisely. Specific services include the following:

Anti-Obesity Cell Therapy Development

We genetically modify or directly transplant a variety of cells into animal models and evaluate the efficacy and reliability of such therapies. Gene editing strategies include viral and non-viral-based transfection and other precision gene editing techniques.

• Development of adipocyte-based anti-obesity therapies
  It is found that gene editing of white adipocytes to develop into brown fat-like cells improves glucose tolerance and insulin sensitivity and increases energy expenditure in post-transplant obese mice. We genetically modify adipocytes and analyze the physiological conditions of animal models after transplantation to assess the therapeutic efficacy of this therapy.
  • Adipocyte Induction Service
    Our specialized adipocyte induction services give your team the precise tool needed to evaluate novel anti-obesity therapies, explore lipid metabolism, and secure high-quality data early in the pipeline.
  • Beige Adipocyte Cell Therapy Development Service
    Our specialized development platform accelerates preclinical research into beige adipocyte transplantation and activation, turning energy-storing tissue into energy-burning engines. We help therapeutic developers design, validate, and optimize cell-based candidates before they move toward regulatory evaluation.
  • Brown Adipocyte Cell Therapy Development Service
    We help biopharma innovators validate target molecules, analyze metabolic flux, and evaluate cell transplantation strategies in specialized animal models. By focusing heavily on rigorous cellular characterization and functional assays, we help ensure your metabolic candidates show genuine efficacy long before entering clinical design.
  • White Adipocyte Cell Therapy Development Service
    We support biotechnology firms, academic research labs, and pharmaceutical companies in exploring these cellular pathways. By focusing deeply on the mechanism of turning energy-storing white fat into active, energy-burning beige or brown-like fat, we build robust cellular models that can validate your target compounds or gene editing approaches long before clinical implementation.

• Development of Stem Cell-based Anti-Obesity Therapies
  • Mesenchymal stem cell (MSC)
    As a pluripotent stem cell, MSC has the ability to self-renew and differentiate into cell types such as adipocytes. It has a variety of promising properties, including migration to multiple tissues, regulation of proliferation and activation of the immune system, and the potential to differentiate into multiple lineages. MSC therapy is currently being developed as a promising strategy for the treatment of obesity. We develop MSC-based (adipose tissue-derived mesenchymal stem cell, human umbilical cord-derived mesenchymal stromal cell, etc.) anti-obesity therapies and evaluate their effects on obesity, metabolic disorders, etc.
  • Induced pluripotent stem cells (hiPSC)
    In addition to this, we process hiPSC, including gene editing, differentiation, etc., and investigate the impact of this strategy on obesity.

• Development of Chimeric Antigen Receptor (CAR) T-Cell Therapy
  CAR-T cells targeting urokinase plasminogen activator receptor (uPAR) are found to have therapeutic activity in a diet-induced obesity model by promoting weight loss and improving glucose homeostasis. We genetically modify T cells in vitro to target specific loci. The transgenic T cells are then transferred to animals and evaluated for their therapeutic potential.
  • Biomarker Screening and Identification Service
    Our biomarker screening services are designed to be highly versatile, providing critical data across a wide range of therapeutic research areas.
  • ScFv Generation Service
    Our custom ScFv generation services provide the high affinity, biophysical stability, and tissue-penetration capabilities required to move your discovery pipeline forward with confidence.
  • CAR Construction Service
    From single-domain antibody tuning to advanced multi-cistronic vector configurations, our platform delivers high-yield, verified, and endotoxin-free constructs tailored specifically to survive and function in complex tissue environments.
  • CAR-T Gene Packaging and Delivery Service
    Protheragen is dedicated to delivering the high-quality, ultra-pure vector packaging architectures required to advance the next generation of metabolic cell therapies.
  • CAR-T Library Construction Service
    Protheragen provides comprehensive end-to-end preclinical library construction support. We recognize that metabolic receptors differ greatly from classic oncology targets, often exhibiting subtle expression nuances.

• NK Cell Therapy Development Service
  • NK Cell Isolation and Amplification Service
    Our specialized NK cell isolation and amplification service is tailor-made for preclinical researchers investigating how targeted NK cell therapies can mitigate metabolic syndrome, decrease low-grade systemic inflammation, and alter fat tissue distribution. We provide the cellular tools needed to transition your therapeutic concepts from theoretical models into validated preclinical data.
  • NK Testing Service
    By combining precise lipotoxicity simulations with high-fidelity functional, phenotypic, and metabolic assays, we give you the deep biological insights needed to advance your obesity-focused cell therapies or small molecules with total confidence.
  • Peripheral NK Cell Therapy Development Service
    We have built a specialized preclinical development platform dedicated to restoring and optimizing peripheral NK cell therapies specifically tailored to function within these hostile, lipid-dense microenvironments. Our services provide the advanced cell engineering, metabolic reprogramming, and robust in vitro and in vivo validation frameworks required to push promising therapeutic candidates through the preclinical pipeline.

• Macrophage Cell Therapy Development Service
  • Macrophage Cell Isolation and Culture Service
    Protheragen offers specialized services designed specifically to isolate and culture these delicate cells from adipose tissues and other obesity-affected organs. We handle the complex tissue digestion and sorting processes so your team can focus entirely on downstream therapeutic testing.
  • Macrophage Cell Gene Editing Service
    We recognize that reversing this immune imbalance requires precise intervention. Our macrophage cell gene editing service provides preclinical researchers with the tools to reprogram these key immune cells. By precisely knocking out inflammatory hubs or overexpressing protective metabolic pathways, we help teams design next-generation macrophage therapies tailored to correct the underlying biology of obesity.

• Dendritic Cell Therapy Development Service
  • Dendritic Cell Isolation and Culture Service
    By providing exceptionally pure, functionally intact primary dendritic cells isolated from specific tissue types or differentiated from precursors, we empower your discovery pipeline. Whether your goal is to map the phenotypic shift of conventional DCs in obese mouse models or to engineer tolerogenic human DCs to damp down adipose tissue inflammation, our platform delivers the exact cellular foundation you need.
  • Anti-obesity Dendritic Cell Vaccine Development Service
    By modifying DC presentation, we can selectively target or downregulate pathways that promote fat storage and tissue inflammation. This opens a brand-new frontier for biopharma companies looking to build a pipeline beyond standard daily or weekly injections.

• Exosome-based Therapy Development Service
  Our specialized platform provides end-to-end preclinical development services designed to transform exploratory metabolic concepts into highly validated, scalable exosome therapy candidates. By focusing entirely on the preclinical stage, we ensure your therapeutic candidates are rigorously optimized for cargo stability, target specificity, and in vivo efficacy before moving toward large-scale manufacturing.
• Autologous Cell Therapy Development Service
  To successfully transition an autologous obesity therapy from the lab bench to pre-clinical proof-of-concept, you need highly specialized technical tools. Our platforms are built around the unique challenges of handling adipose tissue and fragile immune cells.
• Allogeneic Cell Therapy Development Service
  Protheragen provides specialized preclinical development services to help you transform these cell concepts into robust, scalable candidates. We focus strictly on the early, foundational stages of development, ensuring your cell lines are optimized for metabolic efficacy and safety before you transition toward clinical manufacturing.

Preclinical Studies of Therapies

• Obesity Models: Animal models play a critical role in elucidating the molecular mechanisms of obesity and evaluating the safety and efficacy of new anti-obesity cell therapies. We offer a variety of animal models to support our clients' studies of anti-obesity cell therapies.
  • Diet-induced animal models
  • Gene editing models
  • Other types of models
• Evaluation of cell therapy: Based on state-of-the-art facilities and cutting-edge technology, we perform pharmacodynamic studies, pharmacokinetics studies, bioanalysis, and safety assessments of anti-obesity cellular therapies. We analyze fat metabolism, histology, metabolism-related gene expression, etc., to assess the effect of cell transplantation on obesity and the potential mechanism of action.

  Pharmacodynamics Study

  Pharmacokinetics Study

  Bioanalysis

  Safety Assessment

Workflow

Our flexible and innovative anti-obesity cell therapy development program is a great option to accelerate your research.

Applications

• Type 2 diabetes therapy study: Obesity increases the risk of developing type 2 diabetes. Anti-obesity cell therapies may have great potential in treating this disease as well.
• Metabolic syndrome therapy research: Metabolic syndrome is closely related to obesity and overweight. Anti-obesity cell therapy research provides valuable information for the development of metabolic syndrome therapies.
• Preventive therapy research: The development of anti-obesity cell therapy helps promote the research of personalized obesity prevention strategies.

Advantages

• We provide tailored solutions to specific research needs and complete all experiments from anti-obesity cell therapy development, and animal model construction to preclinical studies.
• Each of our experimental processes is meticulously carried out to ensure the accuracy and consistency of data in anti-obesity cell therapy development projects.
• Our experienced researchers are available to answer any questions our clients may have during their anti-obesity studies.

Our Services

Publication Data

Frequently Asked Questions

What is the potential of gene editing for cell therapy development?

Gene editing is a novel approach to generating cells with enhanced therapeutic potential. New genetic engineering tools and techniques are emerging to better achieve this goal, including improving the function of these cells, enhancing their viability, immunomodulatory properties, etc. Transgenic cells are found to be more efficient in vivo in treating metabolic disorders and reducing obesity symptoms compared to wild-type MSC.

What are the advantages of stem cells?

Stem cells are a class of cells with multidirectional differentiation potential and self-renewal, and are divided into various types, including induced pluripotent stem cells (iPSCs), MSCs, and others. Based on the goodness of stem cells, they have important applications in understanding the molecular mechanisms of obesity, developing new effective anti-obesity drugs, and developing stem cell-based therapies. For example, MSC-based cell therapy has been shown to reduce body weight and improve glucose tolerance in obese mice.

Protheragen offers a flexible anti-obesity cell therapy development service based on deep research into obesity, careful cell selection, and a deep understanding of potential therapeutic mechanisms. We aim to accelerate your obesity therapeutic research with efficient project turnaround. Please feel free to contact us for more information and to discuss further experimental processes.